{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:27:54Z","timestamp":1793755674233,"version":"4.6.1"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":253,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011096","name":"Jazz Pharmaceuticals plc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011096","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research Reports"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.lrr.2026.100610","type":"journal-article","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:56:51Z","timestamp":1789196211000},"page":"100610","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Substituting pegaspargase with recombinant Erwinia asparaginase after hypersensitivity reactions: case series of Canadian adult patients with acute lymphoblastic leukemia"],"prefix":"10.1016","volume":"26","author":[{"given":"Lynn","family":"Savoie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kareem","family":"Jamani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Brandwein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4000-6372","authenticated-orcid":false,"given":"Peng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.lrr.2026.100610_bib0001","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1182\/bloodadvances.2024013346","article-title":"Recombinant Erwinia asparaginase (JZP458) in ALL\/LBL: complete follow-up of the children's oncology group AALL1931 study","volume":"9","author":"Maese","year":"2025","journal-title":"Blood. Adv."},{"key":"10.1016\/j.lrr.2026.100610_bib0002","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.2147\/OTT.S106810","article-title":"Safety, efficacy, and clinical utility of asparaginase in the treatment of adult patients with acute lymphoblastic leukemia","volume":"10","author":"Koprivnikar","year":"2017","journal-title":"Onco. Targets. Ther."},{"issue":"16","key":"10.1016\/j.lrr.2026.100610_bib0003","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.2217\/fon.14.138","article-title":"How to manage asparaginase hypersensitivity in acute lymphoblastic leukemia","volume":"10","author":"Burke","year":"2014","journal-title":"Future. Oncol."},{"issue":"4","key":"10.1016\/j.lrr.2026.100610_bib0004","doi-asserted-by":"crossref","first-page":"748","DOI":"10.3109\/10428194.2015.1101098","article-title":"Asparaginase-associated toxicity in children with acute lymphoblastic leukemia","volume":"57","author":"Hijiya","year":"2016","journal-title":"Leuk. Lymphoma."},{"issue":"3","key":"10.1016\/j.lrr.2026.100610_bib0005","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3324\/haematol.2015.137380","article-title":"Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation","volume":"101","author":"van der Sluis","year":"2016","journal-title":"Haematol."},{"key":"10.1016\/j.lrr.2026.100610_bib0006","series-title":"(asparaginase Erwinia Chrysanthemi (recombinant)-rywn) [package insert]","year":"2024"},{"issue":"1","key":"10.1016\/j.lrr.2026.100610_bib0009","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2141.2009.07712.x","article-title":"Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen","volume":"146","author":"Storring","year":"2009","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.lrr.2026.100610_bib0010","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s00280-002-0466-y","article-title":"Anti-Erwinia asparaginase antibodies during treatment of childhood acute lymphoblastic leukemia and their relationship to outcome: a case-control study","volume":"50","author":"Klug Albertsen","year":"2002","journal-title":"Cancer. Chemother. Pharmacol."},{"issue":"9","key":"10.1016\/j.lrr.2026.100610_bib0011","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2012.43.2070","volume":"31","author":"Vrooman","year":"2013","journal-title":"J. Clin. Oncol."}],"container-title":["Leukemia Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048926000506?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048926000506?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:10:29Z","timestamp":1793754629000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213048926000506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":9,"alternative-id":["S2213048926000506"],"URL":"https:\/\/doi.org\/10.1016\/j.lrr.2026.100610","relation":{},"ISSN":["2213-0489"],"issn-type":[{"value":"2213-0489","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Substituting pegaspargase with recombinant Erwinia asparaginase after hypersensitivity reactions: case series of Canadian adult patients with acute lymphoblastic leukemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lrr.2026.100610","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100610"}}